MedImmune’s Greenleaf, Clovis Oncology’s Mahaffy to Deliver Keynotes at 2012 Mid-Atlantic Bio Conference
Two industry-leading executives will deliver keynote addresses at the Mid-Atlantic Bio Conference, the nationally recognized conference taking place on September 27-28 at the Bethesda North Marriott Hotel & Conference in Bethesda, Md.
Patrick J. Mahaffy, president and CEO of Boulder, Colorado-based Clovis Oncology, a biopharmaceutical company, will deliver opening remarks Thursday, September 27. Peter Greenleaf, president of MedImmune, the Gaithersburg, Maryland-based global biologics arm of AstraZeneca, will speak at the Conference’s closing luncheon Friday, September 28.
“The Mid-Atlantic Bio Conference is a great venue to explore the many transformations taking place in our industry and I’m honored to give the opening remarks,” Mahaffy said. “I look forward to sharing my thoughts about company and product development in these interesting and complicated times.”
“Mid-Atlantic Bio plays a vital role in fostering continued growth of the biosciences community and making this region a hub for innovation,” Greenleaf said. “I am honored to have the opportunity to speak at the conference and share insights on the industry trends and forces impacting developing bioscience companies – including opportunities and risks associated with the ongoing U.S. health care reform debate.”
“It is a critical time for the biotech community everywhere, and we are pleased to have Peter and Patrick join us this year to provide their unique perspectives on our industry,” said Art Jacoby, CEO of the Tech Council of Maryland, and one of the conference co-hosts. “This conference is the ideal forum in which we all can convene to share ideas and work to impact the business, financial and policy climates that are imperative to continued innovation and business success.”
